logo

Verrica Pharmaceuticals Inc. (VRCA)



Trade VRCA now with
  Date
  Headline
6/28/2022 7:41:24 AM Verrica Pharmaceuticals Holds Type A Meeting With FDA For VP-102 For Molluscum Contagiosum
5/25/2022 6:41:50 AM Verrica Gets CRL From FDA For VP-102 NDA For The Treatment Of Molluscum Contagiosum
4/5/2022 7:40:31 AM Verrica Pharma Doses First Patient In Phase 2 Study Of LTX-315 For Basal Cell Carcinoma
11/29/2021 7:51:07 AM Verrica Pharma Announces Resubmission Of NDA For VP-102 For Molluscum Contagiosum
11/18/2021 7:40:19 AM Verrica Pharma Announces FDA Acceptance Of IND Application For LTX-315 For Basal Cell Carcinoma
11/12/2021 7:37:38 AM Verrica Pharma Q3 GAAP Net Loss $12.8 Mln Or $0.47/Shr Vs Loss Of $10.5 Mln Or $0.42/Shr Last Year
8/10/2021 9:26:51 AM Verrica Pharma Q2 Loss Per Share $0.43; Non-GAAP Loss Per Share $0.35
7/9/2021 7:58:08 AM Verrica Pharma Appoints Terry Kohler As CFO
3/22/2021 10:45:46 PM Verrica Pharma Prices Public Offering Of 2.03 Mln Shares At $14.75/shr
3/4/2021 7:47:00 AM Verrica Pharmaceuticals Q4 Net Loss $13.0 Mln Vs Loss $7.6 Mln Last Year